3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Neoplasm Metastasis
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Breast Diseases
1
Interventions
pembrolizumab
46
Paclitaxel
42
Carboplatin
34
Bevacizumab
18
Specimen Handling
17
Letrozole
16
lenvatinib
13
Magnetic Resonance Spectroscopy
12
dostarlimab
11
Cisplatin
11
Biopsy
11
olaparib
10
Taxes
10
Fulvestrant
9
Doxorubicin
9
abemaciclib
8
Megestrol Acetate
8
Docetaxel
8
durvalumab
7
atezolizumab
7
Nivolumab
7
Gemcitabine
7
Blood Specimen Collection
7
palbociclib
6
Oxaliplatin
6
Observation
6
Fluorouracil
6
niraparib
5
Tirzepatide
5
Surveys and Questionnaires
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Endometrial Neoplasms
×
STX-478
×
1 year
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled